JCAR-014

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameJCAR-014
Drug Alias NameAutologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center)自体人抗CD19CAR-4-1BB-CD3zeta-EGFRt表达CD4+/CD8+T淋巴细胞-弗莱德哈钦森癌症研究中心huJCAR014Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes huJCAR014Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes huJCAR014 +[8] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD3Anti-CD19
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Large-Cell, AnaplasticLymphoma, Mantle-Cell +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterMemorial Sloan Kettering Cancer CenterSeattle Children'S Research Institute +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesFred Hutchinson Cancer Research CenterJuno Therapeutics Inc
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinHodgkin Disease +[4] 
Inactive IndicationsPrimary mediastinal B cell lymphomaLymphoma, Large-Cell, AnaplasticLymphoma, Mantle-Cell +[10] 

Other Information

ATC CodeN/A
Related LinksN/A